Immusoft Corporation

Immusoft’s mission is the development of an exciting, new breakthrough platform for treating a variety of genetic diseases through a process called Immune System Programming (ISP™). Our technology enables the efficient insertion of genes encoding therapeutic proteins into patients' immune cells (B cells / plasma cells).

LEARN MORE ABOUT THE IMMUSOFT STORY

PROGRAMMING YOUR CELLS TO CURE DISEASE

OUR TEAM

Matt Scholz

Chief Executive Officer

Eric Herbig

Chief Science Officer

Scott McIvor

Chief Development Officer

Zach Hall

Business Development Director

Mei Xu

Research Director

Rian de Laat

Research Scientist

MEET OUR TEAM

ISP™ TECHNOLOGY

Immune System Programming (ISP™) is a breakthrough approach to enable in vivo delivery of gene-encoded medicines (biologics), by re-programming a the patient’s own cells to replace missing or defective enzymes/proteins.

LEARN MORE